Bioengineered Protein Drugs-Europe Market Status and Trend Report 2013-2023
Report Summary
Bioengineered Protein Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bioengineered Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Bioengineered Protein Drugs 2013-2017, and development forecast 2018-2023
Main market players of Bioengineered Protein Drugs in Europe, with company and product introduction, position in the Bioengineered Protein Drugs market
Market status and development trend of Bioengineered Protein Drugs by types and applications
Cost and profit status of Bioengineered Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the Europe Bioengineered Protein Drugs market as:
Europe Bioengineered Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Bioengineered Protein Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Therapeutic Proteins
Monoclonal Antibodies
Vaccines
Europe Bioengineered Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Diabetes and Hormonal Disorders
Genetic and Fertility Disorders
Cancers
Organ Transplants
Others
Europe Bioengineered Protein Drugs Market: Players Segment Analysis (Company and Product introduction, Bioengineered Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Amgen, Inc.
Bayer AG
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
Biocon Ltd.
Eli Lilly and Company
Sanofi
GlaxoSmithKline plc
Johnson & Johnson
JanssenNovartis AG
Panacea Biotec
ProBioGen AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Bioengineered Protein Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bioengineered Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Bioengineered Protein Drugs 2013-2017, and development forecast 2018-2023
Main market players of Bioengineered Protein Drugs in Europe, with company and product introduction, position in the Bioengineered Protein Drugs market
Market status and development trend of Bioengineered Protein Drugs by types and applications
Cost and profit status of Bioengineered Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the Europe Bioengineered Protein Drugs market as:
Europe Bioengineered Protein Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Bioengineered Protein Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Therapeutic Proteins
Monoclonal Antibodies
Vaccines
Europe Bioengineered Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Diabetes and Hormonal Disorders
Genetic and Fertility Disorders
Cancers
Organ Transplants
Others
Europe Bioengineered Protein Drugs Market: Players Segment Analysis (Company and Product introduction, Bioengineered Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Amgen, Inc.
Bayer AG
Merck & Co., Inc.
Dr. Reddy's Laboratories Ltd.
Biocon Ltd.
Eli Lilly and Company
Sanofi
GlaxoSmithKline plc
Johnson & Johnson
JanssenNovartis AG
Panacea Biotec
ProBioGen AG
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOENGINEERED PROTEIN DRUGS
1.1 Definition of Bioengineered Protein Drugs in This Report
1.2 Commercial Types of Bioengineered Protein Drugs
1.2.1 Therapeutic Proteins
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.3 Downstream Application of Bioengineered Protein Drugs
1.3.1 Diabetes and Hormonal Disorders
1.3.2 Genetic and Fertility Disorders
1.3.3 Cancers
1.3.4 Organ Transplants
1.3.5 Others
1.4 Development History of Bioengineered Protein Drugs
1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023
1.5.1 Europe Bioengineered Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Bioengineered Protein Drugs in Europe 2013-2017
2.2 Consumption Market of Bioengineered Protein Drugs in Europe by Regions
2.2.1 Consumption Volume of Bioengineered Protein Drugs in Europe by Regions
2.2.2 Revenue of Bioengineered Protein Drugs in Europe by Regions
2.3 Market Analysis of Bioengineered Protein Drugs in Europe by Regions
2.3.1 Market Analysis of Bioengineered Protein Drugs in Germany 2013-2017
2.3.2 Market Analysis of Bioengineered Protein Drugs in United Kingdom 2013-2017
2.3.3 Market Analysis of Bioengineered Protein Drugs in France 2013-2017
2.3.4 Market Analysis of Bioengineered Protein Drugs in Italy 2013-2017
2.3.5 Market Analysis of Bioengineered Protein Drugs in Spain 2013-2017
2.3.6 Market Analysis of Bioengineered Protein Drugs in Benelux 2013-2017
2.3.7 Market Analysis of Bioengineered Protein Drugs in Russia 2013-2017
2.4 Market Development Forecast of Bioengineered Protein Drugs in Europe 2018-2023
2.4.1 Market Development Forecast of Bioengineered Protein Drugs in Europe 2018-2023
2.4.2 Market Development Forecast of Bioengineered Protein Drugs by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Bioengineered Protein Drugs in Europe by Types
3.1.2 Revenue of Bioengineered Protein Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Bioengineered Protein Drugs in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Bioengineered Protein Drugs in Europe by Downstream Industry
4.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Germany
4.2.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in France
4.2.4 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Italy
4.2.5 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Spain
4.2.6 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Benelux
4.2.7 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Russia
4.3 Market Forecast of Bioengineered Protein Drugs in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
5.1 Europe Economy Situation and Trend Overview
5.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOENGINEERED PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Bioengineered Protein Drugs in Europe by Major Players
6.2 Revenue of Bioengineered Protein Drugs in Europe by Major Players
6.3 Basic Information of Bioengineered Protein Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Players
6.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOENGINEERED PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Abbott Laboratories
7.1.1 Company profile
7.1.2 Representative Bioengineered Protein Drugs Product
7.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.2 F. Hoffmann-La Roche Ltd
7.2.1 Company profile
7.2.2 Representative Bioengineered Protein Drugs Product
7.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd
7.3 Amgen, Inc.
7.3.1 Company profile
7.3.2 Representative Bioengineered Protein Drugs Product
7.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc.
7.4 Bayer AG
7.4.1 Company profile
7.4.2 Representative Bioengineered Protein Drugs Product
7.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.5 Merck & Co., Inc.
7.5.1 Company profile
7.5.2 Representative Bioengineered Protein Drugs Product
7.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.6 Dr. Reddy's Laboratories Ltd.
7.6.1 Company profile
7.6.2 Representative Bioengineered Protein Drugs Product
7.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd.
7.7 Biocon Ltd.
7.7.1 Company profile
7.7.2 Representative Bioengineered Protein Drugs Product
7.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd.
7.8 Eli Lilly and Company
7.8.1 Company profile
7.8.2 Representative Bioengineered Protein Drugs Product
7.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.9 Sanofi
7.9.1 Company profile
7.9.2 Representative Bioengineered Protein Drugs Product
7.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.10 GlaxoSmithKline plc
7.10.1 Company profile
7.10.2 Representative Bioengineered Protein Drugs Product
7.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.11 Johnson & Johnson
7.11.1 Company profile
7.11.2 Representative Bioengineered Protein Drugs Product
7.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.12 JanssenNovartis AG
7.12.1 Company profile
7.12.2 Representative Bioengineered Protein Drugs Product
7.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG
7.13 Panacea Biotec
7.13.1 Company profile
7.13.2 Representative Bioengineered Protein Drugs Product
7.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec
7.14 ProBioGen AG
7.14.1 Company profile
7.14.2 Representative Bioengineered Protein Drugs Product
7.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
8.1 Industry Chain of Bioengineered Protein Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
9.1 Cost Structure Analysis of Bioengineered Protein Drugs
9.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs
9.3 Labor Cost Analysis of Bioengineered Protein Drugs
9.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Bioengineered Protein Drugs in This Report
1.2 Commercial Types of Bioengineered Protein Drugs
1.2.1 Therapeutic Proteins
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.3 Downstream Application of Bioengineered Protein Drugs
1.3.1 Diabetes and Hormonal Disorders
1.3.2 Genetic and Fertility Disorders
1.3.3 Cancers
1.3.4 Organ Transplants
1.3.5 Others
1.4 Development History of Bioengineered Protein Drugs
1.5 Market Status and Trend of Bioengineered Protein Drugs 2013-2023
1.5.1 Europe Bioengineered Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Bioengineered Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Bioengineered Protein Drugs in Europe 2013-2017
2.2 Consumption Market of Bioengineered Protein Drugs in Europe by Regions
2.2.1 Consumption Volume of Bioengineered Protein Drugs in Europe by Regions
2.2.2 Revenue of Bioengineered Protein Drugs in Europe by Regions
2.3 Market Analysis of Bioengineered Protein Drugs in Europe by Regions
2.3.1 Market Analysis of Bioengineered Protein Drugs in Germany 2013-2017
2.3.2 Market Analysis of Bioengineered Protein Drugs in United Kingdom 2013-2017
2.3.3 Market Analysis of Bioengineered Protein Drugs in France 2013-2017
2.3.4 Market Analysis of Bioengineered Protein Drugs in Italy 2013-2017
2.3.5 Market Analysis of Bioengineered Protein Drugs in Spain 2013-2017
2.3.6 Market Analysis of Bioengineered Protein Drugs in Benelux 2013-2017
2.3.7 Market Analysis of Bioengineered Protein Drugs in Russia 2013-2017
2.4 Market Development Forecast of Bioengineered Protein Drugs in Europe 2018-2023
2.4.1 Market Development Forecast of Bioengineered Protein Drugs in Europe 2018-2023
2.4.2 Market Development Forecast of Bioengineered Protein Drugs by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Bioengineered Protein Drugs in Europe by Types
3.1.2 Revenue of Bioengineered Protein Drugs in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Bioengineered Protein Drugs in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Bioengineered Protein Drugs in Europe by Downstream Industry
4.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Germany
4.2.2 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in France
4.2.4 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Italy
4.2.5 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Spain
4.2.6 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Benelux
4.2.7 Demand Volume of Bioengineered Protein Drugs by Downstream Industry in Russia
4.3 Market Forecast of Bioengineered Protein Drugs in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
5.1 Europe Economy Situation and Trend Overview
5.2 Bioengineered Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOENGINEERED PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Bioengineered Protein Drugs in Europe by Major Players
6.2 Revenue of Bioengineered Protein Drugs in Europe by Major Players
6.3 Basic Information of Bioengineered Protein Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Bioengineered Protein Drugs Major Players
6.3.2 Employees and Revenue Level of Bioengineered Protein Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOENGINEERED PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Abbott Laboratories
7.1.1 Company profile
7.1.2 Representative Bioengineered Protein Drugs Product
7.1.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.2 F. Hoffmann-La Roche Ltd
7.2.1 Company profile
7.2.2 Representative Bioengineered Protein Drugs Product
7.2.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd
7.3 Amgen, Inc.
7.3.1 Company profile
7.3.2 Representative Bioengineered Protein Drugs Product
7.3.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen, Inc.
7.4 Bayer AG
7.4.1 Company profile
7.4.2 Representative Bioengineered Protein Drugs Product
7.4.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Bayer AG
7.5 Merck & Co., Inc.
7.5.1 Company profile
7.5.2 Representative Bioengineered Protein Drugs Product
7.5.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.6 Dr. Reddy's Laboratories Ltd.
7.6.1 Company profile
7.6.2 Representative Bioengineered Protein Drugs Product
7.6.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories Ltd.
7.7 Biocon Ltd.
7.7.1 Company profile
7.7.2 Representative Bioengineered Protein Drugs Product
7.7.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Biocon Ltd.
7.8 Eli Lilly and Company
7.8.1 Company profile
7.8.2 Representative Bioengineered Protein Drugs Product
7.8.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
7.9 Sanofi
7.9.1 Company profile
7.9.2 Representative Bioengineered Protein Drugs Product
7.9.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.10 GlaxoSmithKline plc
7.10.1 Company profile
7.10.2 Representative Bioengineered Protein Drugs Product
7.10.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.11 Johnson & Johnson
7.11.1 Company profile
7.11.2 Representative Bioengineered Protein Drugs Product
7.11.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.12 JanssenNovartis AG
7.12.1 Company profile
7.12.2 Representative Bioengineered Protein Drugs Product
7.12.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of JanssenNovartis AG
7.13 Panacea Biotec
7.13.1 Company profile
7.13.2 Representative Bioengineered Protein Drugs Product
7.13.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of Panacea Biotec
7.14 ProBioGen AG
7.14.1 Company profile
7.14.2 Representative Bioengineered Protein Drugs Product
7.14.3 Bioengineered Protein Drugs Sales, Revenue, Price and Gross Margin of ProBioGen AG
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
8.1 Industry Chain of Bioengineered Protein Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
9.1 Cost Structure Analysis of Bioengineered Protein Drugs
9.2 Raw Materials Cost Analysis of Bioengineered Protein Drugs
9.3 Labor Cost Analysis of Bioengineered Protein Drugs
9.4 Manufacturing Expenses Analysis of Bioengineered Protein Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOENGINEERED PROTEIN DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
